评估西尼罗河病毒感染的非人类灵长类动物模型中的单周期黄病毒疫苗 RepliVAX WN。
Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.
机构信息
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
出版信息
Am J Trop Med Hyg. 2010 Jun;82(6):1160-7. doi: 10.4269/ajtmh.2010.09-0310.
Abstract
West Nile virus (WNV) causes serious neurologic disease, but no licensed vaccines are available to prevent this disease in humans. We have developed RepliVAX WN, a single-cycle flavivirus with an expected safety profile superior to other types of live-attenuated viral vaccines. In this report we describe studies examining RepliVAX WN safety, potency, and efficacy in a non-human primate model of WNV infection. A single immunization of four rhesus macaques with RepliVAX WN was safe and elicited detectable neutralizing antibody titers and IgM and IgG responses, and IgG titers were increased in two animals that received a second immunization. After challenge with WNV, three of four immunized animals were completely protected from viremia, and the remaining animal showed minimal viremia on one day. In contrast, the unvaccinated animal developed viremia that lasted six days. These results demonstrate the efficacy and safety of RepliVAX WN in this primate model of WNV infection.
摘要
西尼罗河病毒（WNV）可引起严重的神经疾病，但目前尚无可用的人类预防该疾病的疫苗。我们开发了 RepliVAX WN，这是一种单周期黄病毒，其预期安全性优于其他类型的减毒活病毒疫苗。在本报告中，我们描述了在西尼罗河病毒感染的非人灵长类动物模型中研究 RepliVAX WN 的安全性、效力和疗效的研究。单次免疫 4 只恒河猴用 RepliVAX WN 是安全的，并引起可检测的中和抗体滴度和 IgM 和 IgG 反应，并且在接受第二次免疫的两只动物中 IgG 滴度增加。在接受 WNV 挑战后，四分之三的免疫动物完全免受病毒血症的影响，而其余动物在一天内仅表现出轻微的病毒血症。相比之下，未接种疫苗的动物的病毒血症持续了六天。这些结果表明 RepliVAX WN 在这种西尼罗河病毒感染的灵长类动物模型中具有疗效和安全性。
相似文献
1
Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.评估西尼罗河病毒感染的非人类灵长类动物模型中的单周期黄病毒疫苗 RepliVAX WN。
Am J Trop Med Hyg. 2010 Jun;82(6):1160-7. doi: 10.4269/ajtmh.2010.09-0310.
2
RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters.RepliVAX WN是一种用于预防西尼罗河疾病的单周期黄病毒疫苗，可在仓鼠体内引发持久的保护性免疫。
Vaccine. 2009 Sep 18;27(41):5550-3. doi: 10.1016/j.vaccine.2009.07.016. Epub 2009 Jul 25.
3
Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.针对西尼罗河病毒的减毒活疫苗的神经毒性保证：与两种亲本病毒和一种黄病毒替代参考疫苗相比，对嵌合WN/DEN4Δ30疫苗感染后的神经发病机制进行的综合研究。
Vaccine. 2014 May 30;32(26):3187-97. doi: 10.1016/j.vaccine.2014.04.002. Epub 2014 Apr 13.
4
The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.灭活西尼罗河疫苗（WN-VAX）在小鼠和猴子身上的功效。
Virol J. 2015 Apr 9;12:54. doi: 10.1186/s12985-015-0282-8.
5
TLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidate.TLR3 和 MyD88 依赖性信号通路在接种单周期黄病毒候选疫苗 RepliVAXWN 后对小鼠体内西尼罗河病毒特异性 B 细胞反应的发展具有不同影响。
J Virol. 2013 Nov;87(22):12090-101. doi: 10.1128/JVI.01469-13. Epub 2013 Aug 28.
6
Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system.使用新型培养系统繁殖的第二代伪感染性西尼罗河病毒疫苗的构建与特性分析
Vaccine. 2008 May 23;26(22):2762-71. doi: 10.1016/j.vaccine.2008.03.009. Epub 2008 Mar 31.
7
Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.分子工程化的减毒活嵌合西尼罗河/登革热病毒疫苗可保护恒河猴免受西尼罗河病毒感染。
Virology. 2003 Sep 15;314(1):190-5. doi: 10.1016/s0042-6822(03)00450-1.
8
Baboon model for West Nile virus infection and vaccine evaluation.用于西尼罗河病毒感染和疫苗评估的狒狒模型。
Virology. 2006 Nov 10;355(1):44-51. doi: 10.1016/j.virol.2006.06.033. Epub 2006 Aug 10.
9
Replication-Defective West Nile Virus with NS1 Deletion as a New Vaccine Platform for Flavivirus.复制缺陷型西尼罗河病毒 NS1 缺失突变体作为黄病毒新型疫苗平台。
J Virol. 2019 Aug 13;93(17). doi: 10.1128/JVI.00720-19. Print 2019 Sep 1.
10
Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys.重组亚单位西尼罗河病毒疫苗在恒河猴中的免疫原性和保护效力
Clin Vaccine Immunol. 2009 Sep;16(9):1332-7. doi: 10.1128/CVI.00119-09. Epub 2009 Jul 29.
引用本文的文献
1
Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development.蚊虫传播的黄病毒疫苗研发的最新进展
Viruses. 2023 Mar 23;15(4):813. doi: 10.3390/v15040813.
2
An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults.一项观察者设盲、随机化、安慰剂对照、I 期剂量递增试验，旨在评估健康成年人中使用灭活西尼罗河病毒疫苗（HydroVax-001）的安全性和免疫原性。
Vaccine. 2019 Jul 9;37(30):4222-4230. doi: 10.1016/j.vaccine.2018.12.026. Epub 2019 Jan 18.
3
A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen.Toll样受体4激动剂与皂苷佐剂联合使用可增加重组西尼罗河病毒抗原的抗体多样性和保护效力。
NPJ Vaccines. 2018 Sep 26;3:39. doi: 10.1038/s41541-018-0077-1. eCollection 2018.
4
Nonhuman primate models of human viral infections.人类病毒感染的非人类灵长类动物模型。
Nat Rev Immunol. 2018 Jun;18(6):390-404. doi: 10.1038/s41577-018-0005-7.
5
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond.用于黄病毒感染的广谱药物：登革热、寨卡病毒及其他。
Nat Rev Drug Discov. 2017 Aug;16(8):565-586. doi: 10.1038/nrd.2017.33. Epub 2017 May 5.
6
An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.西尼罗河病毒感染治疗与预防的当前方法概述
Methods Mol Biol. 2016;1435:249-91. doi: 10.1007/978-1-4939-3670-0_19.
7
A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.一种新型合成TLR-4激动剂佐剂可增强多种配方的临床阶段西尼罗河病毒疫苗抗原的保护性反应。
PLoS One. 2016 Feb 22;11(2):e0149610. doi: 10.1371/journal.pone.0149610. eCollection 2016.
8
Vaccines against respiratory viral pathogens for use in neonates: opportunities and challenges.用于新生儿的呼吸道病毒病原体疫苗：机遇与挑战
J Immunol. 2014 Dec 1;193(11):5363-9. doi: 10.4049/jimmunol.1401410.
9
Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus.疫苗诱导恒河猴在经皮内感染欧洲1型西尼罗河病毒株后免受血浆病毒血症影响。
PLoS One. 2014 Nov 13;9(11):e112568. doi: 10.1371/journal.pone.0112568. eCollection 2014.
10
Experimental infection of rhesus macaques and common marmosets with a European strain of West Nile virus.实验性感染欧洲型西尼罗河病毒的恒河猴和普通狨猴。
PLoS Negl Trop Dis. 2014 Apr 17;8(4):e2797. doi: 10.1371/journal.pntd.0002797. eCollection 2014 Apr.
本文引用的文献
1
RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters.RepliVAX WN是一种用于预防西尼罗河疾病的单周期黄病毒疫苗，可在仓鼠体内引发持久的保护性免疫。
Vaccine. 2009 Sep 18;27(41):5550-3. doi: 10.1016/j.vaccine.2009.07.016. Epub 2009 Jul 25.
2
Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system.使用新型培养系统繁殖的第二代伪感染性西尼罗河病毒疫苗的构建与特性分析
Vaccine. 2008 May 23;26(22):2762-71. doi: 10.1016/j.vaccine.2008.03.009. Epub 2008 Mar 31.
3
The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus.抗体和CD8 + T细胞对西尼罗河脑炎病毒疫苗免疫的相对贡献。
Vaccine. 2008 Apr 7;26(16):2020-33. doi: 10.1016/j.vaccine.2008.02.009. Epub 2008 Feb 20.
4
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.一种西尼罗河病毒DNA疫苗在1期临床试验中可诱导健康成年人产生中和抗体。
J Infect Dis. 2007 Dec 15;196(12):1732-40. doi: 10.1086/523650.
5
Differential activation of human monocyte-derived and plasmacytoid dendritic cells by West Nile virus generated in different host cells.西尼罗河病毒在不同宿主细胞中产生后，对人单核细胞衍生树突状细胞和浆细胞样树突状细胞的差异性激活作用。
J Virol. 2007 Dec;81(24):13640-8. doi: 10.1128/JVI.00857-07. Epub 2007 Oct 3.
6
Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production.西尼罗河病毒感染期间I型干扰素的早期产生：淋巴组织在不依赖IRF3的干扰素产生中的作用
J Virol. 2007 Sep;81(17):9100-8. doi: 10.1128/JVI.00316-07. Epub 2007 Jun 13.
7
Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis.一种重组亚单位西尼罗河疫苗候选物在保护仓鼠免受西尼罗河脑炎侵害方面的有效性和持久性。
Vaccine. 2007 Apr 12;25(15):2913-8. doi: 10.1016/j.vaccine.2006.08.008. Epub 2006 Aug 22.
8
Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.嵌合西尼罗河/登革病毒候选疫苗：在小鼠、鹅和猴子中进行的安全性和免疫原性临床前评估。
Vaccine. 2006 Sep 29;24(40-41):6392-404. doi: 10.1016/j.vaccine.2006.06.008. Epub 2006 Jun 21.
9
Production and characterization of vaccines based on flaviviruses defective in replication.基于复制缺陷型黄病毒的疫苗的生产与特性研究
Virology. 2006 Aug 1;351(2):432-43. doi: 10.1016/j.virol.2006.04.003. Epub 2006 May 18.
10
A live, attenuated recombinant West Nile virus vaccine.一种减毒活重组西尼罗河病毒疫苗。
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6694-9. doi: 10.1073/pnas.0601932103. Epub 2006 Apr 14.
Zotero 插件